Diabetes

Explore the complexities of Diabetes research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against Diabetes with flcube.com.

Novo Nordisk Licenses Nanexa's PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Nanexa’s PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes

Nanexa AB (STO: NANEXA), a Swedish drug delivery platform company, announced a global exclusive license and collaboration agreement with Novo Nordisk (NYSE: NVO) for the use of the PharmaShell technology…

European Commission Revokes Hansoh's Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

European Commission Revokes Hansoh’s Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyPolicy / Regulatory

HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026

CompanyDeals

Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement

CompanyDeals

Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio

CompanyDeals

Novo Nordisk to Acquire Inversago Pharma in a Deal Valued Up to USD 1.1 Billion

Company

Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales

CompanyDeals

Oramed Pharmaceuticals and Hefei Tianhui Biotech to Form Joint Venture for Oral Insulin Product

CompanyDrug

Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease

CompanyLegal / IP

Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case

Show More